John T. Price

John T. Price

Auto-generated profile, based on publicly available information

John T. Price

College of Health and Biomedicine, Victoria University, St Albans, Australia

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 December 2010 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
CFClare G. Fedele
Clare G. Fedele
LOLisa M. Ooms
Lisa M. Ooms
MHMiriel Ho
Miriel Ho
JVJessica Vieusseux
Jessica Vieusseux
SOSandra A. O'TOole
Sandra A. O'TOole
CMChristina A. Mitchell
Christina A. Mitchell
Inositol polyphosphate 4-phosphatase-II (INPP4B) is a regulator of the phosphoinositide 3-kinase (PI3K) signaling pathway and is implicated as a tumor suppressor in epithelial carcinomas. INPP4B loss of heterozygosity (LOH) is detected in some human breast cancers; however, the expression of INPP4B protein in breast cancer subtypes and the normal breast is unknown. We report here that INPP4B is expressed in nonproliferative estrogen receptor (ER)-positive cells in the normal breast, and in ER-positive, but not negative, breast cancer cell lines. INPP4B knockdown in ER-positive breast cancer cells increased Akt activation, cell proliferation, and xenograft tumor growth. Conversely, reconstitution of INPP4B expression in ER-negative, INPP4B-null human breast cancer cells reduced Akt activation and anchorage-independent growth. INPP4B protein expression was frequently lost in primary human breast carcinomas, associated with high clinical grade and tumor size and loss of hormone receptors and was lost most commonly in aggressive basal-like breast carcinomas. INPP4B protein loss was also frequently observed in phosphatase and tensin homolog (PTEN)-null tumors. These studies provide evidence that INPP4B functions as a tumor suppressor by negatively regulating normal and malignant mammary epithelial cell proliferation through regulation of the PI3K/Akt signaling pathway, and that loss of INPP4B protein is a marker of aggressive basal-like breast carcinomas.

22 January 2010 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
DDDimitri A. Diavatopoulos
Dimitri A. Diavatopoulos
Kirsty ShortKirsty Short
Kirsty Short
JPJohn T. Price
John T. Price
JWJonathan J. Wilksch
Jonathan J. Wilksch
LBLorena Brown
Lorena Brown
OWOdilia L. Wijburg
Odilia L. Wijburg
Streptococcus pneumoniae (the pneumococcus) kills ~1.6 million people annually. Pneumococcal infections predominantly manifest as pneumonia, sepsis, meningitis, and otitis media. S. pneumoniae is also a member of the normal nasopharyngeal flora, colonizing up to 80% of children. Infection with influenza A virus (IAV) has been associated with both pneumococcal disease and transmission. However, to date no animal model has been available to investigate the role of IAV in the spread of S. pneumoniae . Here we investigate pneumococcal‐influenza synergism with a particular focus on the role of IAV on pneumococcal transmission. Infant mice were colonized with S. pneumoniae and subsequently infected with IAV 3 d later. Using this novel model we show increased pneumococcal colonization and disease in the presence of IAV. Notably, in vivo imaging showed that IAV was essential for the transmission of S. pneumoniae from colonized (“index”) mice to their naive cohoused littermates (“contacts”). Transmission occurred only when all mice were infected with IAV and was prevented when an IAV‐neutralizing antibody was used to inhibit IAV replication in either index mice or contact mice. Together, these data provide novel insights into pneumococcal‐influenza synergism and may indicate a previously unappreciated role of IAV in the spread of S. pneumoniae . —Diavatopoulos, D. A, Short, K. R., Price, J. T., Wilksch, J. J., Brown, L. E., Briles, D. E., Strugnell, R. A, Wijburg, O. L. Influenza A virus facilitates Streptococcus pneumoniae transmission and disease. FASEB J . 24, 1789–1798 (2010). www.fasebj.org

1 January 1997 in Critical Reviews in Biochemistry and Molecular Biology
Verified
Journal Article
Closed access
PDF file
JPJohn T. Price
John T. Price
MBMaria T. Bonovich
Maria T. Bonovich
EKElise C. Kohn
Elise C. Kohn
DWDanny R. Welch
Danny R. Welch
MHMilton S. Hershey
Milton S. Hershey
The progression of a tumor cell from one of benign delimited proliferation to invasive and metastatic growth is the major cause of poor clinical outcome of cancer patients. Recent research has revealed that this complex process requires many components for successful dissemination and growth of the tumor cell at secondary sites. These include angiogenesis, enhanced extracellular matrix degradation via tumor and host-secreted proteases, tumor cell migration, and modulation of tumor cell adhesion. Each individual component is multifaceted and is discussed within this review with respect to historical and recent findings. The identification of components and their interrelationship have yielded new therapeutic targets leading to the development of agents that may prove effective in the treatment of cancer and its metastatic progression.

1 June 2005 in Cancer Research
Verified
Journal Article
Closed access
PDF file
JPJohn T. Price
John T. Price
JQJulian M.W. Quinn
Julian M.W. Quinn
NSNatalie A. Sims
Natalie A. Sims
JVJessica Vieusseux
Jessica Vieusseux
KWKelly Waldeck
Kelly Waldeck
ETErik Walter Thompson
Erik Walter Thompson
Breast cancer metastasis to the bone occurs frequently, causing numerous complications including severe pain, fracture, hypercalcemia, and paralysis. Despite its prevalence and severity, few effective therapies exist. To address this, we examined whether the heat shock protein 90 (Hsp90) inhibitor, 17-allylamino-17-demethoxygeldanamycin (17-AAG), would be efficacious in inhibiting breast cancer metastasis to bone. Utilizing the human breast cancer subline, MDA-MB-231SA, previously in vivo selected for its enhanced ability to generate osteolytic bone lesions, we determined that 17-AAG potently inhibited its in vitro proliferation and migration. Moreover, 17-AAG significantly reduced MDA-MB-231SA tumor growth in the mammary-fat pad of nude mice. Despite these findings, 17-AAG enhanced the incidence of bone metastasis and osteolytic lesions following intracardiac inoculation in the nude mouse. Consistent with these findings, 17-AAG enhanced osteoclast formation 2- to 4-fold in mouse bone marrow/osteoblast cocultures, receptor activator of nuclear factor κB ligand (RANKL)–stimulated bone marrow, and RAW264.7 cell models of in vitro osteoclastogenesis. Moreover, the drug enhanced osteoclastogenesis in human cord blood progenitor cells, demonstrating that its effects were not limited to mouse models. In addition to 17-AAG, other Hsp90 inhibitors, such as radicicol and herbimycin A, also enhanced osteoclastogenesis. A pro-osteolytic action of 17-AAG independent of tumor presence was also determined in vivo, in which 17-AAG–treated tumor-naïve mice had reduced trabecular bone volume with an associated increase in osteoclast number. Thus, HSP90 inhibitors can stimulate osteoclast formation, which may underlie the increased incidence of osteolysis and skeletal tumor incidence caused by 17-AAG in vivo. These data suggest an important contraindication to the Hsp90 targeted cancer therapy currently undergoing clinical trial.

1 March 2003 in Laboratory Investigation
Verified
Journal Article
Open access
PDF file
MAMargaret L Ackland
Margaret L Ackland
DNDonald F Newgreen
Donald F Newgreen
MFMasha Fridman
Masha Fridman
MWMark C Waltham
Mark C Waltham
AAAngela Arvanitis
Angela Arvanitis
ETErik Walter Thompson
Erik Walter Thompson
Article PMC42-LA cells display an epithelial phenotype: the cells congregate into pavement epithelial sheets in which E-cadherin and β-catenin are localized at cell–cell borders. They abundantly express cytokeratins, although 5% to 10% of the cells also express the mesenchymal marker vimentin. Stimulation of PMC42-LA cells with epidermal growth factor (EGF) leads to epithelio-mesenchymal transition–like changes including up-regulation of vimentin and down-regulation of E-cadherin. Vimentin expression is seen in virtually all cells, and this increase is abrogated by treatment of cells with an EGF receptor antagonist. The expression of the mesenchyme-associated extracellular matrix molecules fibronectin and chondroitin sulfate proteoglycan also increase in the presence of EGF. PMC42-LA cells adhere rapidly to collagen I, collagen IV, and laminin-1 substrates and markedly more slowly to fibronectin and vitronectin. EGF increases the speed of cell adhesion to most of these extracellular matrix molecules without altering the order of adhesive preference. EGF also caused a time-dependent increase in the motility of PMC42-LA cells, commensurate with the degree of vimentin staining. The increase in motility was at least partly chemokinetic, because it was evident both with and without chemoattractive stimuli. Although E-cadherin staining at cell–cell junctions disappeared in response to EGF, β-catenin persisted at the cell periphery. Further analysis revealed that N-cadherin was present at the cell–cell junctions of untreated cells and that expression was increased after EGF treatment. N- and E-cadherin are not usually coexpressed in human carcinoma cell lines but can be coexpressed in embryonic tissues, and this may signify an epithelial cell population prone to epithelio-mesenchymal–like responses.

1 August 2015 in Cancer Cell
Verified
Journal Article
Closed access
LOLisa M. Ooms
Lisa M. Ooms
LBLauren C. Binge
Lauren C. Binge
EDElizabeth M. Davies
Elizabeth M. Davies
PRParvin Rahman
Parvin Rahman
JCJames Conway
James Conway
CMChristina A. Mitchell
Christina A. Mitchell